Featured News See All August 25, 2026 REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli August 24, 2026 REGENXBIO Announces Regulatory Update on RGX-121 for MPS II August 6, 2026 REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2009 Aug 25, 2026 REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli Aug 24, 2026 REGENXBIO Announces Regulatory Update on RGX-121 for MPS II Aug 06, 2026 REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights Aug 03, 2026 REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights Jul 18, 2026 REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting Jul 17, 2026 REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants Jul 16, 2026 REGENXBIO Announces Proposed Public Offering of Common Stock
Aug 03, 2026 REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
Jul 18, 2026 REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
